Triplet therapy with pirtobrutinib, venetoclax, and rituximab as a two-year fixed-duration therapy improves progression free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared to standard of care venetoclax plus rituximab therapy, according to interim data from the randomized, phase 3 BRUIN CLL-322 clinical trial. Matthew Davids, MD, MMSc, Chief of the Division of Lymphoma at Dana-Farber Cancer Institute, presented the results in the Late-Breaking Abstract session at the European Hematology Association 2026 Congress in Stockholm, Sweden, on June 14, 2026.

Endocrine-disrupting chemicals (EDCs) that interfere with hormones were found in breast milk and in the urine of children from birth up to 6 months, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.

Longer lifetime exposure to female hormones may increase the risk of thyroid cancer in women, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill. The research suggests reproductive and hormonal factors may be involved in thyroid carcinogenesis.

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions. The approval is based on results from the phase 3 LITESPARK-022 trial, led by Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute.

Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These “persister” cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment.  

A molecular geneticist at Montana State University has discovered a cellular process once believed impossible by scientists – the creation of the amino acid cysteine within a living cell when the cell’s primary systems to do so fail. The discovery may one day lead to new cancer treatments.

About The Study: In this cross-sectional study, following the implementation of an organized population screening program, colorectal cancer screening participation increased and socioeconomic disparities narrowed over time. Overall uptake in Hong Kong remains low, and some disparities persist in younger age groups (age 50-59 years), single households, individuals with a primary and secondary school education, lower-income groups, and public housing residents. Efforts to increase participation are needed in certain groups to ensure health equity.

A carefully designed metal-free carbon monoxide prodrug may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine. The recent preclinical study, published in Advanced Science, offers a new strategy to potentially reduce the recurrence of pancreatic and triple-negative breast cancer in patients who initially respond to treatment.